Saturday 17 October 2026
Export VKTX’s income statement to Excel — free account
Viking Therapeutics, Inc.
VKTX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 89.7% and free cash flow fell 166.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
25.17
2.20
−8.04%
Follow VKTX
Viking Therapeutics, Inc. (VKTX) P/E ratio
Viking Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| VKTX Viking Therapeutics, Inc. | n/m |
| TNGX Tango Therapeutics, Inc. compare | n/m |
| TARS Tarsus Pharmaceuticals, Inc. compare | n/m |
| RLAY Relay Therapeutics, Inc. compare | n/m |
| XENE Xenon Pharmaceuticals Inc. compare | n/m |
| IDYA IDEAYA Biosciences, Inc. compare | n/m |
| ACAD ACADIA Pharmaceuticals Inc. compare | 8.5× |
| ARQT Arcutis Biotherapeutics, Inc. compare | 131× |
| TLX Telix Pharmaceuticals Limited compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)